Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150014/S058

cobas HBV

Roche Molecular Systems, Inc. · Decision date Sep 19, 2025

FDA DECISIONP150014/S058

What did the FDA approve?

FDA records P150014/S058 as a supplement to PMA P150014, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 19, 2025.

FDA approval order statement

cobas HPV for use on the cobas 5800/6800/8800 Systems (cobas HPV) is a qualitative in vitro test for the detection of high-risk Human Papillomavirus. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 in the specimens listed below. Clinician-collected cervical specimens should be obtained using an endocervical brush/spatula or broom and placed in the ThinPrep Pap Test PreservCyt Solution. Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained. cobas HPV is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of individuals with a cervix to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Microbiology
Decision date
Sep 19, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P150014/S058
Regulatory pathway
PMA supplement
Product code
MKT
Decision code
APPR
Decision date
Sep 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hepatitis Viral B DNA Detection.

Product code
MKT
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P150014/S058 received

    Application receipt date recorded by FDA.

  2. P150014/S058 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P150014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150014

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HBVP150014/S057
Roche Molecular Systems, Inc.PMA supplementAug 7, 2025FDA
cobas HBVP150014/S056
Roche Molecular Systems, Inc.PMA supplementOct 17, 2025FDA

Explore the linked device profile

Other records with product code MKT

Product / regulatory recordCompanyPathwayDecision dateSource
Alinity m HBVP200013/S027
Abbott Molecular, Inc.PMA supplementOct 17, 2025FDA
Hologic, Inc.PMA supplementOct 7, 2025FDA
Alinity m HBVP200013/S026
Abbott Molecular, Inc.PMA supplementSep 24, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records